# US 2025/0152501 A1 · Dissolving microneedle for transdermal delivery of biopharmaceutical, and manufacturing method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152501 A1
- Document ID: US20250152501A1
- Status: Published application
- Kind: A1
- Application number: 18/833,780
- Filed: 2022-08-18
- Published: 2025-05-15
- Earliest claimed: 2022-01-28
- Assignees: Dongguk University Industry-Academic Cooperation Foundation
- Applicants: Dongguk University Industry-Academic Cooperation Foundation
- Inventors: Hyo Kyung HAN; Jae Guen SONG
- Web page: https://patentgrep.com/patent/US20250152501A1

## CPC

- A61K 9/0021: {Intradermal administration, e.g. through microneedle arrays or needleless injectors}
- A61K 38/26: Glucagons
- A61K 38/28: Insulins
- A61K 47/30: Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/54: the modifying agent being an organic compound
- A61K 47/69: the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to a dissolving microneedle for transdermal delivery of biopharmaceuticals and a method of manufacturing the same. In the dissolving microneedle of the present disclosure, since biopharmaceuticals form a nanocomposite with aminoclay, the stability of the biopharmaceuticals and the mechanical strength of the microneedle are high, and the skin permeability of the biopharmaceutical is increased, thereby greatly improving transdermal delivery efficiency.

## Claims

### Claim 1

A dissolving microneedle, comprising:
a nanocomposite of a biopharmaceutical and aminoclay; and
a hydrophilic polymer.

### Claim 2 (depends on 1)

The dissolving microneedle of claim 1, wherein the biopharmaceutical is at least one selected from the group consisting of biological preparations, genetic recombinant medicines, cell culture medicines, peptide medicines, protein medicines, and antibody medicines.

### Claim 3 (depends on 1)

The dissolving microneedle of claim 1, wherein the biopharmaceutical has an isoelectric point of 9 or less.

### Claim 4 (depends on 1)

The dissolving microneedle of claim 1, wherein the biopharmaceutical is a protein medicine, and
the protein medicine is at least one selected from the group consisting of lilaglutide, teriparatide, insulin, insulin analogs, glucagon-like peptide-1 (GLP-1), GLP-2, semaglutide, exenatide, exendin-4, lixisenatide, taspoglutide, albiglutide, dulaglutide, oxyntomodulin, amylin, somatostatin analogs, goserelin, buserelin, leptin, glatiramer acetate, leuprolide, osteocalcin, human growth hormone (hGH), glycopeptide antibiotics, bortezomib, cosyntropin, menotropins, gonadotropin releasing hormone (GnRH), somatropin, calcitonin, oxytocin, lepirudin, carfilzomib, icatibant, and aldesleukin.

### Claim 5 (depends on 1)

The dissolving microneedle of claim 1, wherein the aminoclay is a 3-aminopropyl group-introduced metal phyllosilicate.

### Claim 6 (depends on 5)

The dissolving microneedle of claim 5, wherein the metal is magnesium (Mg).

### Claim 7 (depends on 1)

The dissolving microneedle of claim 1, wherein the hydrophilic polymer comprises at least one selected from the group consisting of hyaluronic acid, poly vinyl alcohol, poly vinyl pyrrolidone, carboxymethyl cellulose, a vinylpyrrolidone-vinyl acetate copolymer, and polyglycolic acid.

### Claim 8 (depends on 1)

The dissolving microneedle of claim 1, wherein the dissolving microneedle comprises 1 wt % to 10 wt % of the biopharmaceutical, 1 wt % to 10 wt % of aminoclay, and 80 wt % to 98 wt % of the hydrophilic polymer, based on the total weight of the dissolving microneedle.

### Claim 9 (depends on 1)

A patch comprising the dissolving microneedle of claim 1.

### Claim 10

A method of manufacturing a dissolving microneedle, the method comprising:
(i) mixing a biopharmaceutical and aminoclay to form a biopharmaceutical-aminoclay nanocomposite;
(ii) mixing the biopharmaceutical-aminoclay nanocomposite with a hydrophilic polymer;
(iii) injecting a mixture produced in step (ii) into a microneedle mold; and
(iv) separating a microneedle from the microneedle mold after drying.

### Claim 11 (depends on 10)

The method of claim 10, wherein the biopharmaceutical is at least one selected from the group consisting of biological preparations, genetic recombinant medicines, cell culture medicines, peptide medicines, protein medicines, and antibody medicines.

### Claim 12 (depends on 10)

The method of claim 10, wherein the aminoclay is 3-aminopropyl group-introduced metal phyllosilicate.

### Claim 13 (depends on 2)

The dissolving microneedle of claim 2, wherein the biopharmaceutical is a protein medicine, and
the protein medicine is at least one selected from the group consisting of lilaglutide, teriparatide, insulin, insulin analogs, glucagon-like peptide-1 (GLP-1), GLP-2, semaglutide, exenatide, exendin-4, lixisenatide, taspoglutide, albiglutide, dulaglutide, oxyntomodulin, amylin, somatostatin analogs, goserelin, buserelin, leptin, glatiramer acetate, leuprolide, osteocalcin, human growth hormone (hGH), glycopeptide antibiotics, bortezomib, cosyntropin, menotropins, gonadotropin releasing hormone (GnRH), somatropin, calcitonin, oxytocin, lepirudin, carfilzomib, icatibant, and aldesleukin.

### Claim 14 (depends on 3)

The dissolving microneedle of claim 3, wherein the biopharmaceutical is a protein medicine, and
the protein medicine is at least one selected from the group consisting of lilaglutide, teriparatide, insulin, insulin analogs, glucagon-like peptide-1 (GLP-1), GLP-2, semaglutide, exenatide, exendin-4, lixisenatide, taspoglutide, albiglutide, dulaglutide, oxyntomodulin, amylin, somatostatin analogs, goserelin, buserelin, leptin, glatiramer acetate, leuprolide, osteocalcin, human growth hormone (hGH), glycopeptide antibiotics, bortezomib, cosyntropin, menotropins, gonadotropin releasing hormone (GnRH), somatropin, calcitonin, oxytocin, lepirudin, carfilzomib, icatibant, and aldesleukin.
